Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has been assigned a consensus recommendation of “Moderate Buy” from the four ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $382.00.

Several research firms recently commented on MEDP. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and upped their price target for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Robert W. Baird upped their price objective on shares of Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Finally, StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd.

Medpace Trading Up 1.2 %

Shares of NASDAQ:MEDP opened at $402.30 on Friday. The firm has a 50 day simple moving average of $386.80 and a 200-day simple moving average of $314.19. Medpace has a twelve month low of $185.43 and a twelve month high of $419.42. The company has a market capitalization of $12.46 billion, a PE ratio of 45.30, a P/E/G ratio of 2.16 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 12th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.22 by $0.24. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The firm had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. During the same quarter in the prior year, the firm earned $2.12 EPS. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. As a group, equities research analysts predict that Medpace will post 10.53 EPS for the current fiscal year.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock valued at $76,651,647 in the last ninety days. 25.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medpace

A number of large investors have recently added to or reduced their stakes in the business. Rheos Capital Works Inc. acquired a new stake in Medpace in the 1st quarter valued at about $9,942,000. Congress Asset Management Co. MA grew its stake in Medpace by 1.3% in the 1st quarter. Congress Asset Management Co. MA now owns 155,406 shares of the company’s stock valued at $62,807,000 after acquiring an additional 2,012 shares during the last quarter. Rise Advisors LLC acquired a new stake in Medpace in the 1st quarter valued at about $27,000. Mather Group LLC. acquired a new stake in Medpace in the 1st quarter valued at about $28,000. Finally, First Hawaiian Bank grew its stake in Medpace by 4.3% in the 1st quarter. First Hawaiian Bank now owns 2,973 shares of the company’s stock valued at $1,202,000 after acquiring an additional 122 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.